Skip to main content
. Author manuscript; available in PMC: 2010 Jan 15.
Published in final edited form as: Cancer Res. 2009 Jan 15;69(2):565–572. doi: 10.1158/0008-5472.CAN-08-3389

Figure 4.

Figure 4

Western blot analysis of the biochemical response of MDAMB231 cells treated with MEK inhibitor CI1040, EGFR inhibitor gefitinib, or their combination in low (0.1% FBS) and full (10% FBS) serum conditions. Cells were harvested at 4 h after drug treatment. In low serum conditions and in the presence of EGF, MEK inhibition results in strong phosphorylated EGFR (p-EGFR) and p-AKT up-regulation, which is abrogated by EGFR inhibitor.

HHS Vulnerability Disclosure